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AbstrAct
Urine from patients with prostate 
cancer (PCa) contains gene 
transcripts that have been used for 
PCa diagnosis and prognosis. Histor-
ically, patient urine samples have 
been collected after a digital rectal 
examination of the prostate, which 
was thought necessary to boost the 
levels of prostatic secretions in the 
urine. We herein describe method-
ology that allows urine to be collected 
by patients at home and then posted 
to a laboratory for analysis. RNA 
yields and quality were comparable 
to those for post digital rectal exami-
nation urine, and there was improved 
sensitivity for the detection of 
TMPRSS2:ERG transcripts by RT-PCR. 
The At-Home collection protocol has 
opened up the potential to perform 
large-scale PCa studies without the 
inconvenience, cost, discomfort and 
expense of patients having to visit 
the clinic.
Method suMMAry
The use of a commercial preservative 
allowed samples to be maintained at 
room temperature without loss of RNA quality. 
Harvest of cell-free RNA using a novel high-
volume vacuum extraction method increased 
total RNA yields, improved the detection sensi-
tivity of prostate-cancer-specific transcripts 
by RT-PCR, enabled extraction of RNA from 
historic frozen urine samples, and allowed the 
harvest of sRNA. Comparisons between digital 
rectal examination (DRE) and non-DRE urine 
RNA yields and RT-PCR expression levels have 
demonstrated that the collection of non-DRE 
urine by men at home is a viable and simple 
option.
Prostate cancer (PCa) is present in nearly 
half of all men over 60 years [1]; however, 
only a very small proportion of these men 
will die of PCa [2]. Determining which men 
have disease that requires treatment is an 
ongoing clinical problem. Furthermore, the 
majority of PCa cases are multi-
focal [3–5] and tumors with different Gleason 
patterns can exist in individual prostates [3], 
adding complexity to disease monitoring 
and assessment. The zones of the prostate 
where tumors are found constantly produce 
secretions that naturally flow into the 
urethra [6]. These secretions carry cancer 
cells and cell-free RNA (cfRNA) contained 
within extracellular vesicles [7] that are 
flushed out of the body upon urination. RNA 
can be harvested from urine and examined 
for the presence of PCa transcripts and 
prognostic markers. Recent successes in 
this field include three studies, two carried 
out on whole urine and one on cfRNA [8–10]. 
All three papers generated similar AUROC 
(area under the receiver operating charac-
teristics) curves of 0.73 to 0.78 for the 
detection of significant cancer (cancer with 
a pathological Gleason score of ≥7). The 
study by Connell et al. [8] also identified 
predictors of disease progression in active 
surveillance patients up to 5 years after a 
single urine sample (hazard ratio: 8.23; 95% 
CI: 3.26–20.81; p < 0.001). These studies and 
the PCA3 test all measure transcripts in urine 
collected after a digital rectal examination 
(DRE) of the prostate, which boosts levels 
of prostate transcripts in the urine [11]. A DRE 
involves a clinician inserting a finger into the 
rectum and firmly stroking the entire 
posterior side of the prostate. There are a 
number of issues with the DRE. There is 
variation in the size and position of the 
prostate, which may not be easily acces-
sible [12]. A DRE depresses only the posterior 
side of the prostate, thus increasing the 
detection of cancers on that side of the 
prostate relative to anterior cancers. Also, a 
DRE requires a visit to a clinic, and DREs are 
unpopular with patients [13]. McKiernan 
et al. [14] recently demonstrated that cfRNA 
extracted from non-DRE urine collected in 
the clinic could be used to detect significant 
PCa with a comparable AUROC of 0.77 [15]. 
However, we have found that non-DRE urine 
collected in the clinic is highly variable and 
can have very poor yields of RNA [8]. We 
hypothesize that this is due to men urinating 
immediately prior to seeing a doctor and 
thus depleting prostate secretions from the 
urethra.
Here we describe an at-home collection 
system for acquiring urine from the first 
micturition of the day for diagnostic and 
prognostic use. This at-home collection 
protocol will allow the utility of urine to 
be explored more widely and easily, will 
minimize costly and stressful visits to the 
clinic, and could lead to the implementation 
of an early intervention test for PCa akin to 
that used for colorectal cancer [16]. This 
method also has the potential to be used 
in a wider arena to detect other urological 
malignancies present in bladder and kidney 
tissues.
Materials & Methods
Manufacturer and catalog number infor-
mation for all items used in this study are 
presented in the Supplementary data.
Urine sample collection
Urine samples (first ≤30 ml voided) were 
collected from men attending urology clinics 
at the Norfolk and Norwich University 
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Hospital. Samples were either taken before 
biopsy or collected more than 3 months after 
biopsy. Ethical approval was obtained from 
the East of England Research Ethics 
Committee (IRAS project ID 96199, REC 
reference 12/EE/0058). A pre-addressed, 
first-class postage-prepaid, leakproof 
SafeBox container was included in all of the 
at-home kits. In this study, all samples were 
received from donors within 3 days of 
collection.
rNa extraction
Each sample was centrifuged at 2500 ×g for 
5 min. Supernatant was filtered through a 
0.8-mm filter, and the cell pellet was stored 
in 1 ml phosphate-buffered saline at -80°C. 
RNA was extracted from the cell sediment 
with a Qiagen RNeasy® kit following the 
manufacturer’s instructions. cfRNA was 
extracted from urine supernatant by two 
methods. In method one, microfiltration 
(MicroF) was used to harvest urine extracel-
lular vesicles (EVs) [8,15,17]. Briefly, EVs were 
filter harvested from 10 ml urine by centrifu-
gation at 4000 ×g in a 100-kDa cut-off MicroF 
device. EV RNA was then extracted using a 
Qiagen RNeasy kit following the manufac-
turer’s instructions. For method two, high-
volume vacuum extraction (HiVE), which 
works by drawing large-volume samples over 
a Norgen RNA-binding column by vacuum 
using a 25-ml disposable pipette as a large-
volume reservoir (see Supplementary data 
for the complete protocol). Further volumes 
of urine can be drawn up into the same 
pipette for extraction on the same 
RNA-binding column as necessary. The 
Norgen column binds both large and small 
RNAs. The small RNA (<150 nt) and large 
RNA (>150 nt) were separated using a Zymo 
RNA column (RNA Clean & Concentrator-5) 
following the manufacturer’s instructions. 
RNA quantity was assessed using a Qubit 
2.0 Fluorometer and Qubit RNA HS Assay. 
RNA quality was determined using a Bioan-
alyzer 2100 and the RNA 6000 Pico kit. sRNA 
yield was assessed with an Agilent sRNA kit. 
For methodology development, urine 
samples from three to seven men collected 
on the same day were mixed together.
RNA amplification & PCR
RNA (10–20 ng) was reverse transcribed and 
amplified using the Ovation Pico WTA 
System V2 kit (NuGEN, catalog code 
3312–48) following the manufacturer’s 
instructions to generate 2–4 μg cDNA, which 
was used to seed PCRs. (The PCR primers 
and conditions are provided in the Supple-
mentary data.) Due to the high rate of PCa 
found in the general population (∼30% of 30- 
to 40-year-old men [18]), urine from men 
proven to be PCa negative was not available. 
Instead, every set of RT-PCRs contained 
negative-control tubes consisting of PCR 
reaction mix to which no cDNA had been 
added; all of these cDNA-negative controls 
were negative for PCR product in all cases. 
PCR product yield was assessed in a 
semiquantitative manner using Image J 
software following the method of Antiabong 
et al. [19].
Results & disCussioN
Comparison of cell sediment & cfRNA
RNA was extracted from the cell sediment 
and cell-free supernatant fractions of 201 
urine samples. A microfiltration method (see 
Materials & methods) was used to harvest 
EVs from urine supernatant with a 100-kDa 
cut-off filter [8]. Both cell sediment and 
cfRNA were then extracted with an RNeasy 
kit (Qiagen, Germany). Yields varied widely 
among samples. Mean cfRNA yields (252 ng) 
were significantly lower than mean cell RNA 
yields (412 ng; p < 0.001, Wilcoxon). Pairwise 
analysis of individual samples demonstrated 
that there was no evidence of even a weak 
correlation between cell and cfRNA yields 
(Pearson r = 0.086) (Figure 1A).
RNA (10 ng) was amplified prior to 
TaqMan analysis with a whole transcriptome 
amplification kit (see Materials & methods), 
10 ng of cDNA was used in each PCR and 
transcript levels were calculated relative 
to this input amount. TaqMan quantitative 
RT-PCR (qRT-PCR) was performed to directly 
compare the relative amounts of transcript 
levels of three prostate-related genes in 
paired-cell and cfRNA samples. These 
three gene transcripts were selected for 
their proven usefulness in analyzing urine 
for the presence of PCa [11,20,21]: KLK3, a 
prostate-specific transcript that encodes 
prostate-specific antigen (PSA) (n = 87) 
and two transcripts overexpressed in PCa; 
PCA3 (prostate cancer antigen 3; n = 84); and 
OR51E2/PSGR (prostate-specific G-protein 
coupled receptor; n = 80). Transcript levels 
in cancer samples were significantly higher 
in cfRNA compared with cell pellet RNA for 
KLK3 (>4×; mean CT = 25.0 vs 27.5), OR51E2 
(>8×; CT = 24.9 vs 28.3) and PCA3 (32×; 
CT = 21.3 vs 26.2) (all p < 0.05, Wilcoxon) 
(Figure 1B–D).
These results suggest that in general 
the vast majority of KLK3, PCA3 and OR51E2 
transcripts in whole urine originate in the 
cell-free EV fraction. PCa cells have been 
reported to be a small fraction of the many 
types of cells found in urine which include 
inflammatory cells, urothelial cells, umbrella 
cells, squamous cells and mature sperm [22]. 
In contrast, the majority of EV RNA appears 
to arise from the prostate [8]. These observa-
tions led us to investigate cfRNA biomarkers 
further.
Variation in rNa yields from post-dre 
urine samples
We examined the urine cfRNA yields 
extracted by the MicroF method from 315 
men after DREs performed by one of six 
different clinicians. Clinicians were advised 
to perform three strokes per prostate lobe 
as recommended for the PCA3 test [11], and 
urine was then collected ∼10 min later. RNA 
yields for all DRE samples varied from 0.1 to 
2200 ng (mean, 214 ng). Some of this 
variation is associated with the clinician 
performing the DRE, as median RNA yields 
varied greater than eightfold among the six 
clinicians (30–244 ng; p < 0.001, Kruskal-
Wallis) (Figure 1E), suggesting that the DRE 
technique can influence RNA yield. RNA 
yields from 14 non-DRE samples collected 
in the clinic were significantly lower in 
comparison (range, <1–140 ng; median, 
<1 ng; p < 0.001, Wilcoxon).
Urine preservative, cfrNa yield & 
integrity
MicroF cfRNA yields decreased rapidly when 
urine was maintained without preservative 
(Figure 2A & C) and decreased further with 
losses of up to 52% after 6 months of storage 
at -80°C (Figure 2A). MicroF yields of RNA 
from seven urine samples stored at -80°C 
for 3 years were <1 ng in six of the seven 
samples (see below and Figure 4).
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Two urine preservatives were tested: 
Hologic, which is used in the PCA3 urine 
test [11] (1:1 dilution per the manufacturer’s 
instructions), and Norgen (1:25 dilution). The 
preservatives were initially tested with five 
urine supernatant samples stored at -80°C 
and extracted with the MicroF protocol. 
Samples were divided into three aliquots (no 
preservative, Norgen preservative or Hologic 
preservative), which were then subdivided 
into five aliquots and stored at -80°C for up 
to 6 months. cfRNA was extracted on the day 
of urine collection, after 1 week, and after 1, 
3 and 6 months and was assessed by yield 
(Qubit) and integrity (Bioanalyzer) (Figure 2A 
& B). Yields from preserved samples were 
better than those for the nonpreserved 
samples, with up to 10% higher yields even 
on the day of collection (paired urine sample 
comparison; p < 0.05, Wilcoxon). cfRNA 
yields from non-preserved urine continued to 
drop over the next 6 months while preserved 
urine yields stabilized. Yields were similar 
for both preservatives at 6 months. RNA 
integrity, as measured by the Bioanalyzer 
RNA integrity number (RIN), was remarkably 
stable after 6 months in Norgen preser-
vative and was much better than for the 
Hologic preservative (example RINs: 6.3 and 
4.2, respectively) (Figure 2B). The Norgen 
preserved urine samples (1:25 dilution) were 
more economical on freezer space than the 
Hologic samples (1:1 dilution). The urine 
standard operating procedure for this study 
required only a single freeze/thaw cycle. The 
effects of further freeze/thaw cycles were 
not tested.
The efficacy of the HiVE method of 
extraction (see below) for whole urine stored 
at room temperature up to 1 week with or 
without Norgen preservative was examined 
on three samples. At time 0, 1 h and 1, 2 and 
7 days the cell sediment was removed and 
cfRNA extracted. The initial rapid drop in 
cfRNA yield after 1 h was reduced by the 
Norgen preservative. Nonpreserved sample 
cfRNA yields dropped further by ∼25% in the 
first 48 h and continued to drop, whereas the 
preserved sample yields remained stable 
(Figure 2B & C). RNA integrity from 7-day-old 
non-preserved urine was poor compared 
with the preserved urine (example RINs: 1.8 
and 6.1, respectively) (Figure 2D), and the 
mean yield from preserved urine samples 
(347 ng) was higher than for non-preserved 
samples (198.2 ng; p = 0.1, Wilcoxon). Preser-
vative manufacturer Norgen states that 
urine samples remain viable for use for up 
to 2 years at room temperature.
rNa extraction method by MicroF & 
hiVe
The MicroF method harvests extracellular 
vesicles by microsieving [14,15,17]. We have 
processed >900 samples by this method and 
have encountered problems with frequent 
blockage of the expensive microfiltration 
units and extremely poor yields when 
extracting cfRNA from historic frozen unpre-
served urine (see below and Figure 4A). We 
examined other published methods of 
extracting RNA, all of which had some disad-
vantages (e.g., time consuming, expensive, 
low input volume and vesicle selection) (see 
Supplementary Table 1). We therefore set 
out to devise a simpler and cost-effective 
means of extracting RNA from large volumes 
(≥10 ml) of urine supernatant without having 
to harvest the EVs first. HiVE works by using 
a large-volume reservoir that fits into the top 
of a standard RNA extraction spin column 
 
Figure 1. Cell RNA, cell-free RNA yields, and gene-transcript levels. (A) RNA yields from cell-free 
supernatant (yellow) (MicroF extraction protocol) aligned with cell sediment yields (green) from 
the same urine sample (n = 201). Samples are ordered from left to right based on increasing cfRNA 
yield. (B–D) qRT-PCR average CT values from triplicate analyses of paired cell sediment and cfRNA 
samples from patients with PCa for KLK3, PCA3 and OR51E2. Median CT values were consistently 
higher in the cell pellet fractions, indicating lower transcript levels. (E) MicroF cfRNA yields from 
288 men following a DRE performed by one of six different clinicians; the numbers of samples 
collected per clinician are in brackets beneath. Horizontal blue lines indicate the highest and lowest 
median yields from the six clinicians. The ‘Non-DRE clinic’ samples were 14 samples collected in 
the clinic without a DRE.
cfRNA: Cell-free RNA; CT: Threshold cycle; DRE: Digital rectal examination; MicroF: Microfiltration; 
PCa: Prostate cancer.
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such as the Qiagen RNeasy column. A 30-ml 
disposable plastic pipette works well as a 
reservoir with no leakage problems (see 
Figure 3 and Supplementary data for 
equipment setup). The RNeasy column is 
positioned on a Qiagen vacuum manifold, 
and the urine/lysis mixture is pulled through 
the RNA binding column under vacuum. 
Further volumes of urine/lysis binding media 
can be drawn over the same RNA column if 
required. HiVE was initially tested with a 
Qiagen RNeasy column, but subsequently 
we tested a Zymo RNA column that has a 
lower elution volume (10 ml instead of 20 ml) 
and a Norgen RNA column (silicon carbide-
based) that binds a larger size range of 
RNAs, including small RNAs. Yields for 
cfRNA were >1.4-fold higher (p = 0.0052, 
Wilcoxon) when using the Norgen column 
(Figure 4A). HiVE yields were higher than 
those for MicroF even after separation of 
sRNA (Figure 4A). Flow-through times for 
the Norgen column were much slower 
(∼30 min) than for Qiagen or Zymo (∼3 min), 
which may account for some of this 
increased yield.
The manufacturer’s protocol for Norgen 
column extraction involves multiple repet-
itive spinning and the re-addition of sample/
reagent mix to the Norgen column, making 
it incompatible with vacuum extraction. To 
combine the increased binding capabilities 
of the Norgen column with the simplicity of 
the Qiagen method, we tested the Qiagen 
RNeasy RLT lysis buffer with the Norgen 
RNA binding column and found that the 
system worked well. Norgen columns and 
Qiagen RLT buffer can be purchased as 
separate items. The total RNA (HiVE-total) 
was then subdivided into large RNA and 
small RNA fractions using a Zymo RNA 
column that only strongly binds RNA over 
∼200 nucleotides. Additional ethanol was 
then added to the eluate, which was applied 
to a Zymo column for binding and elution of 
the small RNA fraction (see Supplementary 
data for full details). The large and small RNA 
fractions were referred to as HiVE-lRNA and 
HiVE-sRNA, respectively. Total RNA from the 
Norgen column had a tendency to slowly 
degrade at -80°C over a period of 1 month; 
however, performing Zymo size separation 
and cleanup within 24 h was found to 
stabilize and maintain RNA integrity.
hiVe & MicroF cfrNa yields
cfRNA yields for HiVE and MicroF extraction 
were directly compared in ten pooled urine 
samples (urine from 3 to 7 men in each pool) 
on the day of collection. Median RNA yields 
for HiVE-total and HiVE-lRNA were 102 and 
93 ng, respectively, compared with 57 ng 
from the MicroF method (see Figure 4Aii). 
We investigated whether the lower MicroF 
cfRNA yields were due to cfRNA passing 
through the 100-kDa microfilter. To this end, 
we used the HiVE method to extract RNA 
from the 100-kDa flow-through. Mean total 
RNA yield was 18 ng, accounting for ∼35% 
of the difference in yields between the 
MicroF and HiVE total RNA extractions. 
HiVE-sRNA was in the size range of 
microRNAs and sRNAs (Supplementary 
Figure 1). Yields from 10 samples ranged 
from 0 to 69 ng (mean, 25 ng). The utility of 
HiVE to extract cfRNA from historic whole 
urine frozen without preservative for up to 
3 years was investigated. Whole urine 
samples (n = 7) were thawed at 4°C for 4 h 
and cell sediment removed. cfRNA yields 
were ∼21-fold higher with HiVE (p = 0.002, 
Kruskal-Wallis) (Figure 4A) than with MicroF 
extraction.
PCR analysis of RNA extracted by 
MicroF & hiVe
Ten urine samples were extracted by both 
MicroF and HiVE and examined by PCR for 
levels of three transcripts (see Materials & 
methods): KLK2 (prostate-specific), 
TMPRSS2:ERG fusion gene transcripts 
(PCa-specific, present in ∼50% of PCa), and 
PCA3 (overexpressed in PCa). As MicroF 
cfRNA yields were often <100 ng, all samples 
used for PCR were first amplified as cDNA 
using the NuGEN WTA kit [23]. PCR products 
were quantified by band intensity on agarose 
gels using Image J software [19,24,25]. There 
was no credible evidence that KLK2 product 
yields were significantly different (median 
yields, 30 ng for HiVE vs 40 ng for MicroF; 
p = 0.089, Wilcoxon) (Figure 4B). Product 
yields and the sensitivity of detection of 
TMPRSS2:ERG were significantly higher for 
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HiVE RNA (8/10 positive) than MicroF RNA 
(5/10 positive), with median product yields 
for MicroF being less than a fifth of those for 
HiVE (3 ng vs 21 ng; p = 0.015, Wilcoxon). The 
reason for this was hypothesized to be the 
Millipore 100-kDa filter used in the MicroF 
method having some selective effect on the 
extracellular vesicles, in contrast to HiVE, 
which has no prior selection procedure.
at-home collection of non-dre urine 
samples for PCa biomarker analysis
We examined whether the consistency of 
urine biomarker levels could be improved by 
collecting urine from patients at home from 
their first micturition of the day. We imple-
mented the technical improvements entailed 
above into an at-home collection protocol 
using Norgen preservative and HiVE 
extraction (see Figure 5 & Supplementary 
data for more information about the at-home 
collection kit and protocol for urine 
collection). The 30-ml tubes used for 
collection contained Norgen preservative 
that had been dried to the bottom of the tube 
overnight under vacuum (also available 
predried from Norgen; see Supplementary 
data). The dried preservative remained in 
place at the bottom of the tube during 
transport to the patient and dissolved over 
a period of 20 min after the addition of urine. 
Capped tubes were placed in a sealable 
plastic bag with wadding and sent to the 
laboratory in a leakproof SafeBox container. 
Study information and two consent forms 
were provided to the patient in the kit, along 
with a telephone contact number if further 
information was required.
Fourteen men were enrolled to provide 
three urine samples: post-DRE urine in the 
clinic, non-DRE urine collected from the first 
micturition of the day at home (H0), and a 
non-DRE sample collected at home 1 h later 
(H1), which was used to examine how much 
cfRNA can accumulate in 1 h. Yields of cfRNA 
were comparable for post-DRE samples and 
at-home collected samples (median yield 
comparisons all p > 0.05, Wilcoxon test) 
(Figure 6A). PCR was performed for KLK2, 
PCA3 and TMPRSS2:ERG. In pairwise compar-
isons of PCR product yields, no statistically 
significantly differences were found for KLK2 
and PCA3, but TMPRSS2:ERG was found to 
differ significantly between DRE and home-
collected samples (DRE vs H0, p = 0.009; 
DRE vs H1, p = 0.029; H0 vs H1, p = 0.52, 
Wilcoxon). TMPRSS2:ERG was detectable 
in 8 out of 14 H0 and H1 samples but was 
only detectable in 3 out of 14 post-DRE 
clinic samples (p = 0.12; Fisher’s exact test) 
(Figure 6B). We hypothesize that this low rate 
of detection in DRE samples may be due to 
earlier urination in the hospital depleting PCa 
biomarkers from the urethra prior to urine 
collection; alternatively, it may imply the 
presence of anterior tumors.
 
Figure 2. Urine preservative tests. (A) Microfiltration cell-free RNA yields from five urine super-
natants stored at -80°C without preservative or with either Norgen or Hologic preservative for up 
to 6 months. Urine samples were extracted from 2 ml supernatant on the day of collection, after 
1 week, and after 1, 3 and 6 months. (B) Bioanalyzer assessment of RNA samples from sample 1 in 
Figure 2A. (C) High-volume vacuum extraction RNA yields from three whole urine samples stored 
at room temperature with and without Norgen urine preservative extracted at time 0, at 1 h and at 
1, 2 and 7 days. (D) Bioanalyzer traces for representative samples from Figure 2B. Urine was stored 
at room temperature for 7 days with Norgen preservative (lower panel) and without preservative 
(upper panel).
 
Figure 3. RNA high-volume vacuum extraction (HiVE). (A) Overview of the vacuum manifold setup 
for extraction of RNA from urine. (B) Close-up of a 25-ml pipette inserted into the Norgen RNA 
column; no additional support for the column is required. Urine is slowly pulled through the Norgen 
column under vacuum (∼30 min).
Reports
www.BioTechniques.com6 No. 2 | Vol. 68 | © 2019 Jeremy Clark
Although the effect of nycturia on the H0 
samples is unknown, it is notable that the 
rates of detection of PCA3 and TMPRSS2:ERG 
PCR products in H0 samples were higher 
than in the post-DRE samples. Median levels 
of PCR products in H0 samples were 11–33% 
higher than for samples collected 1 h later 
(H1) (Figure 6). From these data, we hypoth-
esize that a minimum of 2 or 3 h could be 
required for transcript levels to reach those 
of the H0 samples; therefore, in our letter 
to the patient, we asked them to provide a 
urine sample after a minimum of 3 h of sleep. 
Ejaculation is expected to deplete prostate 
biomarkers and may have other unknown 
effects on the prostate urine risk test. For 
this reason, it may be necessary to request 
that the patient wait 24 h after sexual activity 
before providing a sample.
FutuRe PeRsPeCtive
The methodology and at-home collection 
protocol in this paper offer a simple and cost-
effective means of testing and monitoring 
men for PCa. We intend to use this method-
ology to implement a clinical test for 
aggressive PCa within the next 10 years. The 
collection of urine from men at home avoids 
the randomness of DRE and can increase 
the levels of PCa biomarkers in the urine. 
Connell et al. [8] have shown that an elevated 
‘prostate urine risk’ (PUR) signature can be 
used to identify aggressive PCa, thus 
avoiding overdiagnosis and identification of 
indolent disease. The at-home collection 
protocol could revolutionize how men with 
PCa on active surveillance are monitored for 
disease progression, as men would have to 
visit the clinic only for a positive urine result, 
which is preferable to the current situation 
where they are recalled to the clinic every 
6–12 months for PSA testing and painful and 
expensive biopsies. A negative result for the 
prostate urine risk signature test could allow 
men to be retested only every 2–3 years, 
reducing both patient stress and hospital 
workloads. This protocol will also enable 
screening for other urinary cancers such as 
bladder and kidney.
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Figure 4. RNA yields and RT-PCR values for microfiltration and high-volume vacuum extraction 
(HiVE). (A) RNA yields were examined for the following variables: (i) Total RNA yields extracted 
from 10-ml urine samples (n = 10) by HiVE using RNA binding columns from three manufacturers 
(Norgen, Qiagen and Zymo). (ii) RNA yields from 10 samples extracted on the day of urine collection 
by MicroF and HiVE (HiVE-total RNA and HiVE-lRNA (>200 nt)). (iii) RNA yields from historic urine 
samples (10-ml) stored at -80°C without preservative for 3 years (n = 7) extracted by both MicroF 
and HiVE. (B) PCR product yields for KLK2 and TMPRSS2/ERG transcripts in the samples extracted 
by both MicroF and HiVE.
HiVE: High-volume vacuum extraction; MicroF: Microfiltration; lRNA: LargeRNA >200nt.
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Figure 5. Contents of the at-home collection kit. (A) Invitation to participate. (B) Study infor-
mation sheet. (C) Two urine collection tubes (30 ml) containing dried Norgen preservative. (D) 
Two consent forms (one for the patient to keep and the other to return with the samples). (E) 
Disposable non-allergenic glove. (F) Pen (to write the time and date on the tubes). (G) 1-h frog timer. 
(H) Sealable plastic bag with wadding. (I) Preaddressed postage-paid SafeBox for returning the 
samples.
 
Figure 6. Post-digital rectal examination and at-home collection samples. (A) HiVE-lRNA yields 
from 20 men from whom three urine samples were collected. DRE indicates urine collected in the 
clinic post-DRE; H0, urine collected at home first thing in the morning (time 0); and H1, a second 
urine sample collected at home 1 h later. RNA was extracted from 10 ml of the 30 ml of urine 
collected. (B) Home collection samples (n = 14) were analyzed by RT-PCR for three transcripts 
(KLK2, TMPRSS2:ERG and PCA3).
DRE: Digital Rectal Examination; HiVE: High-volume vacuum extraction.
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